NEKTAR THERAPEUTICS (NKTR) has 5 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 3 sales totalling $441K. Most recent filing: Aug. 20, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 20, 2026 filed Aug. 18, 2026 | Zalevsky Jonathan Chief R&D Officer | −$13,388 | 186 | −2% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | ROBIN HOWARD W President & CEO | −$30,088 | 418 | −1% | No | |
|
|
||||||
| July 24, 2026 | Zalevsky Jonathan Chief R&D Officer | $0 | 16,500 | 0% | No | |
|
|
||||||
| July 24, 2026 | ROBIN HOWARD W President & CEO | $0 | 57,200 | 0% | No | |
|
|
||||||
| July 2, 2026 filed June 30, 2026 | Zalevsky Jonathan Chief R&D Officer | −$397,670 | 5,681 | −37% | Yes | |
|
|
||||||
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free